Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline variants and impact on lung cancer outcomes following chemotherapy: A systematic review.

Critical reviews in oncology/hematology·2026
Same author

To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.

Diabetes care·2026
Same author

Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study.

Diabetes care·2026
Same author

Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data.

The Lancet. Primary care·2026
Same author

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.

Genome medicine·2026
Same author

Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events.

BMC medical genomics·2026
Same journal

Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness.

Current diabetes reports·2026
Same journal

Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.

Current diabetes reports·2026
Same journal

Climate Change and Diabetes Outcomes: Evidence from Climate-Vulnerable Regions.

Current diabetes reports·2026
Same journal

Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.

Current diabetes reports·2026
Same journal

Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.

Current diabetes reports·2026
Same journal

Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments.

Current diabetes reports·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Pharmacogenetics in diabetes.

Ewan R Pearson1

  • 1Biomedical Research Institute, Ninewells Hospital and Medical School, Ninewells Avenue, Dundee, DD1 9SY, UK. e.pearson@chs.dundee.ac.uk

Current Diabetes Reports
|March 28, 2009
PubMed
Summary
This summary is machine-generated.

Genetic variations influence how well diabetes medications work and their side effects. Pharmacogenetics offers hope for personalized diabetes treatment by understanding these genetic links.

Related Experiment Videos

Last Updated: Jun 24, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Internal Medicine

Background:

  • Genetic variations can affect the efficacy and safety of oral antidiabetic agents.
  • Metformin's mechanism is unclear, but transporters may play a role in its response.
  • Cytochrome P450 involvement in sulfonylurea response is suggested, but pharmacodynamic variants are more promising.

Purpose of the Study:

  • To explore the impact of genetic variations on the response to common oral antidiabetic medications.
  • To identify specific genes and genetic variants associated with drug efficacy and adverse events.
  • To highlight the potential of pharmacogenetics in understanding drug and disease mechanisms.

Main Methods:

  • Review of existing studies on genetic variations and drug response.
  • Identification of candidate genes involved in drug metabolism and pharmacodynamics.
  • Mention of genome-wide association studies (GWAS) as a key methodology.

Main Results:

  • Pharmacokinetic gene variations may influence metformin response.
  • Variants in ABCC8 (SUR1) and TCF7L2 are promising for sulfonylurea response.
  • PPARG and ADIPOQ variants show variable associations with thiazolidinedione response.

Conclusions:

  • Genetic factors significantly impact the effectiveness and safety of oral diabetes medications.
  • Pharmacogenetic insights are crucial for unraveling drug and disease mechanisms.
  • Future research with large cohorts and advanced methods like GWAS will enable personalized diabetes therapy based on genotype.